Results from this study demonstrate that in addition to the inhibition of androgen receptor (AR), the key modulator of prostate tumor growth, arctigenin was able to increase the expression of Nkx3.1 and suppress tumor angiogenesis to inhibit prostate tumor growth in obese conditions. Here, NKX3-1 is linked to prostate neoplasm.